Lung cancer personalized medicine! AstraZeneca has partnered with ArcherDX to develop an individualized cancer detection method to identify small residuals in lung cancer!

May 26, 2020 /
BiovalleyBIOON/--
AstraZenecarecently partnered with ArcherDX, a genomics analysis firm focused on precisiononcology, to detect micro-residual disease (minimaldisease, MRD) in patients with early non-small cell lung cancer (NSCLC) with personalized cancer monitoringArcherDX's personalized analysis will be used in AstraZeneca's recently launched Phase III MERMAID-1 trialThe trial, conducted in patients with stage II and Phase III NSCLC with a high risk of recurrence, will assess the effects of anti-PD-L1 therapy Imfinzi (Chinese commodity name: Infiniti, generic name: durvalumab, dwarvalium, dwarvaliu) combination chemotherapy, single-use complementary treatment for non-disease survival (DFS)MRD describes a very small number of undetectable cancer cells that release theDNA of the tumorthe bloodMonitoring the presence of MRD with ctDNA can provide valuable information for determining treatment effectiveness, informing the prognosis, detecting whether the cancer is recurrence, and so onUltimately, MRD testing allows doctors to intervene early and tailor the best treatment for individual cancer patientsin accordance with the terms of the agreement, ArcherDX will perform a full exon sequence of NSCLC patient samples and generate highly sensitive, personalized ctDNA analysis to detect residual MRD after successful surgeryThe TRACERx study, funded by Cancer Research UK and led by the UCL and Francis Crick Institute, provides information on the ongoing development of these analytical methods , AstraZeneca is currently evaluating Imfinzi's treatment for lung cancer in a wide range of clinical development projects, including several ongoing Phase III trials to assess the potential for Imfinzi to cure NSCLC at an early stage "MERMAID-1 is a new randomized trial that uses ctDNA to identify patients at high risk of recurrence after surgery who may benefit from immunotherapy interventions," said Dr Charles Swanton, M.D., an international coordinating researcher in the MERMAID-1 trial and director of the Frances Creek Institute We hope to lead to a better outcome for patients by strengthening the treatment of patients most at risk of relapse, while avoiding additional chemotherapy after surgery "While the detection and monitoring of MRD has proven challenging in the field of physical tumor , the MERMAID-1 trial and this partnership promises to open up new horizons in the field of lung cancer," said Jos? Baselga, Executive Vice President, AstraZeneca Oncology Research and Development This innovative effort reflects our strategy to improve the prognosis of cancer by treating patients early It is in this early environment that the chances of cure are higher, and the identification of personalized and effective treatments can improve survival and quality of life Jason Myers, CEO and Co-Founder of ArcherDX, said: "While progress has been made in improving the use of precision oncology in patients with advanced cancer, there is an urgent need to accelerate access to accurate of oncology for all patients diagnosed with cancer, regardless of the stage or location of treatment AstraZeneca also has this important mission, and we are pleased to work with them to develop biomarker-driven therapies and extend personalized cancer surveillance for all patients "
lung cancer is the leading cause of cancer death in both men and women, accounting for about one-fifth of all cancer deaths Lung cancer is widely divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which 80-85% are NSCLC About 39% of NSCLC patients have limitations or regional lung cancer, and surgery (complete removal) may be an option Up to 60% of phase II-III patients undergoing surgery eventually relapsed Imfinzi (Infyfan, Duvaliu monoantigen) is a humanized PD-L1 monoclonal antibody that blocks the binding of PD-L1 with PD-1 and CD80, thus blocking the immune escape of tumor
and releasing the suppressed immune response To date, Imfinzi has been approved in more than 60 countries (including the United States, Japan, China, and the European Union as a whole) for treatment of non-reprecyibility of non-rectructive, stage III non-small cell lung cancer (NSCLC) patients who have not developed disease progressonomes after platinum-based chemotherapy synchrotron radiotherapy In the United States and Singapore, Imfinzi has also been approved for the first-line treatment of combined standard therapeutic chemotherapy (SoC) for wide-term small cell lung cancer (ES-SCLC) In addition, Imfinzi has been approved in more than 10 countries, including the United States, for advanced bladder cancer patients who have received chemotherapy containing platinum ArcherDX's personalized cancer surveillance (PCM) technology, designed to detect MRD after surgery in early cancer patients, was awarded by the U.S Food and Drug Administration (
The FDA ) granted Breakthrough Device Qualifications ArcherDX plans to use PCM analytics to develop complementary diagnostic for AstraZeneca's selected drugs, and two companies plan to seek regulatory approval if clinical trials successfully completed These analyses are currently used only for research purposes (biovalleybioon.com) original source: AstraZeneca with Archer DX to use personalised cancer assay to minimally siel residual clinic disease in lung cancer trials